### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1-33 (canceled)
- 34 (currently amended) A method of treating a neoplastic disease in an animal <u>in need thereof</u> comprising administering <u>to the animal</u> a therapeutically effective amount of a compound <del>or salt of claim 1 to the animal of the formula (I):</del>

$$R_n$$
 $NH_2$ 
 $N$ 
 $R_2$ 
 $X-O-R_1$ 

<u>(I)</u>

wherein:	X is -CHR3-, -CHR3-alkyl-, or -CHR3-alkenyl-;
	R <sub>1</sub> is selected from the group consisting of:
	-alkenyl;
	-aryl; and
	-R <sub>4</sub> -aryl;
	R <sub>2</sub> is selected from the group consisting of:
	-hydrogen;
	-alkyl;
	alkenyl;
<del></del>	aryl;
	-heteroaryl;
	-heterocyclyl;
	-alkyl-Y-alkyl;

-alkyl-Y- alkenyl;
-alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from the
group consisting of:
OH;
-halogen;
$-N(R_3)_2$ ;
$-\text{CO-N}(R_3)_2;$
$-\text{CO-C}_{1-10}$ alkyl;
aryl;
-heteroaryl;
-heterocyclyl;
CO-aryl; and
-CO-heteroaryl;
R <sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more
—O— groups;
each R <sub>3</sub> is independently H or C <sub>1-10</sub> alkyl;
Y is $-O-$ or $-S(O)_{0-2-}$ ;
n is 0 to 4; and
each R present is independently selected from the group consisting of C <sub>1-10</sub> alkyl,
$C_{1-10}$ alkoxy, hydroxy, halogen and trifluoromethyl;
or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

## 35 (canceled)

36 (currently amended) A method of treating a neoplastic disease in an animal <u>in need thereof</u> comprising administering <u>to the animal</u> a therapeutically effective amount of a compound <del>or salt of claim 11 to the animal of the formula (II):</del>

$$\begin{array}{c|c}
 & N \\
 & N \\$$

wherein	X is -CHR <sub>3</sub> -, -CHR <sub>3</sub> -alkyl-, or -CHR <sub>3</sub> -alkenyl-;
	R <sub>10</sub> is selected from the group consisting of:
	<u>-H;</u>
	-alkyl;
	-alkenyl; and
	-aryl;
	R <sub>2</sub> is selected from the group consisting of:
	-hydrogen;
	-alkyl;
	alkenyl;
	-aryl;
	-heteroaryl;
	-heterocyclyl;
	-alkyl-Y-alkyl;
	-alkyl-Y-alkenyl;
	-alkyl-Y-aryl; and
	-alkyl or alkenyl substituted by one or more substituents selected from the
	group consisting of:
<del></del>	-OH;
	-halogen;
	$-N(R_3)_2$ :
<del></del>	- <u>CO-N(R<sub>3</sub>)2;</u>
	-CO-C <sub>1-10</sub> alkyl;

-CO-O-C<sub>1-10</sub> alkyl;

-N<sub>3</sub>;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

n is 0 to 4;

Y is -O- or  $-S(O)_{0-2}-$ ;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl; and

each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl,

 $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

#### 37-39 (canceled)

40 (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound or salt of claim 21 to the animal of the formula (III):

wherein: X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

R<sub>1</sub> is selected from the group consisting of:

-aryl;
-alkenyl; and

$-R_4$ –aryl;
R <sub>2</sub> is selected from the group consisting of:
-hydrogen;
alkyl;
alkenyl;
aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
alkyl-Y-aryl;
alkyl-Y-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from th
group consisting of:
OH;
-halogen;
$-N(R_3)_2$ ;
$-\text{CO-N}(R_3)_2$ ;
$-\text{CO-C}_{1-10}$ alkyl;
-CO-O-C <sub>1-10</sub> alkyl;
aryl;
heteroaryl;
heterocyclyl;
CO-aryl; and
-CO-heteroaryl;
R <sub>4</sub> is alkyl or alkenyl, which may be interrupted by one or more
<u>–O– groups;</u>
each $R_3$ is independently H or $C_{1-10}$ alkyl;
Y is $-O$ - or $-S(O)_{0-2}$ -;
n is 0 to 4; and

# each R present is independently selected from the group consisting of $C_{1-10}$ alkyl, $C_{1-10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

## 41-45 (canceled)

46 (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (IV):

wherein:

X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

 $R_{10}$  is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

Case No.: 56200US040

```
-alkyl-Y- alkenyl; and
                 - alkyl or alkenyl substituted by one or more substituents selected from the
                 group consisting of:
                         -OH;
                         -halogen;
                         -N(R_3)_2;
                         -CO-N(R_3)_2;
                         -CO-C<sub>1-10</sub> alkyl;
                         -CO-O-C<sub>1-10</sub> alkyl;
                         -N_3;
                         -aryl;
                         -heteroaryl;
                         -heterocyclyl;
                         -CO-aryl; and
                         -CO-heteroaryl;
        each R_3 is independently H or C_{1-10} alkyl;
        Y is -O- or - S(O)_{0-2};
        n is 0 to 4; and
        each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl,
        C_{1\text{--}10} alkoxy, hydroxy, halogen and trifluoromethyl;
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
```

47 (new) A method of inducing cytokine biosynthesis in an animal comprising administering a compound of the formula (IV):

$$NH_2$$
 $NH_2$ 
 $N$ 
 $R_2$ 
 $X-O-(CH_2)_{1-10}$ 
 $X-O$ 
 $(IV)$ 

wherein:

X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

 $R_{10}$  is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

 $R_2$  is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

-alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

 $-N(R_3)_2;$ 

 $-CO-N(R_3)_2;$ 

-CO-C<sub>1-10</sub> alkyl;

-CO-O- $C_{1-10}$  alkyl;

 $-N_3$ ;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each  $R_3$  is independently H or  $C_{1-10}$  alkyl;

Y is -O- or -  $S(O)_{0-2}$ -;

n is 0 to 4; and

each R present is independently selected from the group consisting of  $C_{1-10}$  alkyl,  $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, to the animal in an amount effective for cytokine induction.

48 (new) The method of claim 47 wherein the cytokine is IFN- $\alpha$ .

49 (new) A method of treating a viral disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (IV):

$$NH_2$$
 $NH_2$ 
 $N$ 
 $R_2$ 
 $X-O-(CH_2)_{1-10}$ 
 $X-O$ 
 $(IV)$ 

wherein:

X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

R<sub>10</sub> is selected from the group consisting of:

Case No.: 56200US040

```
-H;
         -alkyl;
         -alkenyl; and
         -aryl;
R<sub>2</sub> is selected from the group consisting of:
         -hydrogen;
         -alkyl;
         -alkenyl;
         -aryl;
         -heteroaryl;
        -heterocyclyl;
         -alkyl-Y-alkyl;
        -alkyl-Y-aryl;
         -alkyl-Y-alkenyl; and
        - alkyl or alkenyl substituted by one or more substituents selected from the
         group consisting of:
                 -OH;
                 -halogen;
                 -N(R_3)_2;
                 -CO-N(R_3)_2;
                 -CO-C_{1-10} alkyl;
                 -CO-O-C<sub>1-10</sub> alkyl;
                 -N_3;
                 -aryl;
                 -heteroaryl;
                 -heterocyclyl;
                 -CO-aryl; and
                 -CO-heteroaryl;
each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;
Y is -O- or - S(O)_{0-2}-;
n is 0 to 4; and
```

Case No.: 56200US040

each R present is independently selected from the group consisting of  $C_{1-10}$  alkyl,  $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

50 (new) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (IV):

$$NH_2$$
 $NH_2$ 
 $N$ 
 $R_2$ 
 $X-O-(CH_2)_{1-10}-C \equiv CR_{10}$ 
(IV)

wherein:

X is –CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or –CHR<sub>3</sub>-alkenyl-;

 $R_{10}$  is selected from the group consisting of:

-H;

-alkyl;

-alkenyl; and

-aryl;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-aryl;

-alkyl-Y- alkenyl; and

- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

```
-OH;
-halogen;
-N(R<sub>3</sub>)<sub>2</sub>;
-CO-N(R<sub>3</sub>)<sub>2</sub>;
-CO-C<sub>1-10</sub> alkyl;
-CO-O-C<sub>1-10</sub> alkyl;
-N<sub>3</sub>;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;
```

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;

Y is -O- or -  $S(O)_{0-2}$ -;

n is 0 to 4; and

each R present is independently selected from the group consisting of  $C_{1-10}$  alkyl,  $C_{1-10}$  alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.